US FDA Approves Lilly's Mounjaro for Cardiovascular Risk Reduction, Expanding GLP-1 Drug Indications
Core Summary The U.S. Food and Drug Administration (FDA) has approved Eli Lilly’s Mounjaro (tirzepatide) for reducing cardiovascular risk, marking a major expansion of GLP-1 drug indications. Previously used primarily for treating type 2 diabetes and obesity, the drug is now proven to significantly reduce the risk of heart attacks and strokes. This decision places Mounjaro in direct competition with Novo Nordisk’s Ozempic in the cardiovascular protection space, signaling a new phase in metabolic disease treatment. ...